Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Content Test Method Validation At Issue In Gummy Vites Dispute

This article was originally published in The Tan Sheet

Executive Summary

A public dispute between vitamin maker Northwest Natural Products and online testing firm over test results highlights issues of test method validation and standard levels for contaminants in the dietary supplement industry

You may also be interested in...

ConsumerLab on multivitamins

Online testing group affirms 25 of 37 multivitamin products evaluated contain the labeled amount of ingredients, disintegrate properly for absorption and do not contain potentially harmful levels of lead, White Plains, N.Y.-based firm announces May 21. Thirteen of the 25 approved products were submitted by their manufacturers for testing under the firm's voluntary certification program. Brands okayed by that were not submitted for testing are Twinlab, GNC,One-A-Day, Walgreens, Women's MultiStart, AARP Health Care Options, Enfamil supplement drops, Propel fitness water and Flintstones. Several failing products contained ingredients in smaller amounts than labeled and at least one product contained a "high amount" of lead, ConsumerLab says...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts